surgoncoКреативная хирургия и онкологияCreative surgery and oncology2076-30932307-0501Башкирский государственный медицинский университет10.24060/2076-3093-2012-0-3-37-40surgonco-131Research ArticleОПЫТ ЛЕЧЕБНЫХ УЧРЕЖДЕНИЙEXPERIENCE OF HEALTHCARE FACILITIESВОЗМОЖНОСТИ ЭНДОСКОПИЧЕСКОГО ОРГАНОСОХРАНЯЩЕГО ЛЕЧЕНИЯ БОЛЬНЫХ ИНВАЗИВНЫМ РАКОМ МОЧЕВОГО ПУЗЫРЯ Т2аN0M0CAPABILITIES OF ENDOSCOPIC ORGAN PRESERVATION TREATMENT OF INVASIVE BLADDER CANCER PATIENTS AT THE STAGE Ò2àN0M0ЗимичевА. А.ZimichevA. A.

Зимичев Александр  Анатольевич - ассистент кафедры  урологии,  кандидат медицинских наук.

443099, Самара, ул. Чапаевская, д. 89, тел. 8 (903) 335-90-59, e-mail: zimichew@mail.ru

zimichew@mail.ruСамарский государственный медицинский университетРоссияSamara State Medical UniversityRussian Federation201230012017033740Copyright © Зимичев А.А., 20172017Зимичев А.А.Zimichev A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surgonco.ru/jour/article/view/131

Применили в лечение пациентов с раком  мочевого пузыря  стадии  Т2аN0M0  сочетание  трансуретральной вапоризации с трансуретральной резекцией и комбинированную химиотерапию (заявка на патент №2010127350/20 (038956) от 5.07.10 «Способ лечения  при  раке  мочевого пузыря»). При анализе результатов лечения  применили разработанную систему  псевдомногофакторного анализа. В исследовании доказано, что использование сочетания  трансуретральной резекции и  вапоризации позволяет снизить  количество рецидивов рака  мочевого пузыря,  снизить  количество осложнений.  Применение в лечение пациентов с раком  мочевого пузыря  стадий  Т2аN0M0 ТУР+ТУЭВ, системной полихимиотерапии и внутрипузырной адъювантной химиотерапии  доксирубицином по схеме позволяет достичь  безрецидивной выживаемости в 93,0% случаев.  Результаты  нашего  исследования показали правомочность применения эндоскопического органосохраняющего лечения  при инвазивных опухолях.

The  combination  of the transurethral  vaporization,  transurethral  resection  of bladder cancer  together with the combined chemotherapy was applied( patent application no. 2010127350/20 (038956) d.d. 5.07.10 “Bladder cancer  treatment method”). The developed system of a pseudo-multifactorial analysis was used to study the treatment results. The study proves that the combination of the transurethral resection and transurethral vaporization lets decrease both the number of bladder cancer  recurrences and the number of complications. The treatment of bladder cancer  patients at the stage Т2аN0M0 with the application of the systemic polychemotherapy and doxorubicin adjuvant chemotherapy according to the schedule lets the recurrence free survival get 93.0%. The results of our research prove the competence of the endoscopic organ preservation treatment to be applied to treat invasive cancers.

инвазивный рак мочевого пузырятрансуретральная резекциявапоризацияхимиотерапияотдаленные результатыinvasive bladder cancertransurethral resectionvaporizationchemotherapylate resultsReferencesHousset M., Dufour E., Maulard-Durtux C. // Concomitant 5-fluouracil (5-FU)-cisplatin (CDDP) and bifractionated split course radiation therapy (BSCRT) for invasive bladder cancer // Proc Am Soc Clin Oncol. – 1997. Vol. 16. – P. 1139.Housset M., Dufour E., Maulard-Durtux C. // Concomitant 5-fluouracil (5-FU)-cisplatin (CDDP) and bifractionated split course radiation therapy (BSCRT) for invasive bladder cancer // Proc Am Soc Clin Oncol. – 1997. Vol. 16. – P. 1139.Rodel C., Grabenbauer G.G., Kuhn R. et al. // Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results // J Clin Oncol. – 2002. – Jul. – Vol. 20(14). – P. 3061–3071.Rodel C., Grabenbauer G.G., Kuhn R. et al. // Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results // J Clin Oncol. – 2002. – Jul. – Vol. 20(14). – P. 3061–3071.Shipley W.U., Kaufman D.S., Zietman A.L. et al. Selective bladder preservation by combined modality therapy for invasive bladder cancer // Eur J Cancer. – 1995. – Vol. 31. №5. – P. 239.Shipley W.U., Kaufman D.S., Zietman A.L. et al. Selective bladder preservation by combined modality therapy for invasive bladder cancer // Eur J Cancer. – 1995. – Vol. 31. №5. – P. 239.Shipley W.U., Kaufman D.S., Heney N.M. et al. An update of selective bladder preservation by combined modality therapy for invasive bladder cancer // Eur Urol. – 1998. – Vol. 33. №4. – P.32–34.Shipley W.U., Kaufman D.S., Heney N.M. et al. An update of selective bladder preservation by combined modality therapy for invasive bladder cancer // Eur Urol. – 1998. – Vol. 33. №4. – P.32–34.Shipley W.U., Kaufman D.S., Zehr E. et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer // Urology. – 2002. Vol. 5. P. 236-242.Shipley W.U., Kaufman D.S., Zehr E. et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer // Urology. – 2002. Vol. 5. P. 236-242.Weiss C., Wolze C., Engehausen D.G. et al. // Radiochemotherapy after transurethral resection for highrisk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy // J Clin Oncol. – 2006. Vol. 5. P. 1041-1078.Weiss C., Wolze C., Engehausen D.G. et al. // Radiochemotherapy after transurethral resection for highrisk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy // J Clin Oncol. – 2006. Vol. 5. P. 1041-1078.Wittlinger M, Rodel C.M., Weiss C. et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia // Radiother Oncol. – 2009. – Vol. 93(2). – P. 358–635.Wittlinger M, Rodel C.M., Weiss C. et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia // Radiother Oncol. – 2009. – Vol. 93(2). – P. 358–635.Zietman A.L., Grocela J., Zehr E. et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder // Urology. 2001. – Sep. – Vol. 58(3). – P. 380–385.Zietman A.L., Grocela J., Zehr E. et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder // Urology. 2001. – Sep. – Vol. 58(3). – P. 380–385.

The authors declare that there are no conflicts of interest present.